48.05
Qiagen Nv stock is traded at $48.05, with a volume of 508.94K.
It is down -0.06% in the last 24 hours and up +6.43% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
See More
Previous Close:
$48.06
Open:
$47.88
24h Volume:
508.94K
Relative Volume:
0.37
Market Cap:
$10.01B
Revenue:
$1.98B
Net Income/Loss:
$83.59M
P/E Ratio:
128.48
EPS:
0.374
Net Cash Flow:
$502.31M
1W Performance:
+1.69%
1M Performance:
+6.43%
6M Performance:
+4.86%
1Y Performance:
+16.07%
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
QGEN
Qiagen Nv
|
48.04 | 10.01B | 1.98B | 83.59M | 502.31M | 0.374 |
![]()
TMO
Thermo Fisher Scientific Inc
|
418.87 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
![]()
DHR
Danaher Corp
|
200.38 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
![]()
IDXX
Idexx Laboratories Inc
|
541.50 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
![]()
A
Agilent Technologies Inc
|
120.26 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
![]()
IQV
Iqvia Holdings Inc
|
162.54 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-04-25 | Downgrade | Redburn Atlantic | Buy → Neutral |
Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
Jan-06-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Dec-10-24 | Upgrade | Jefferies | Hold → Buy |
Oct-17-24 | Downgrade | HSBC Securities | Buy → Hold |
Jun-27-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
Sep-12-23 | Initiated | Robert W. Baird | Outperform |
May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
Oct-15-21 | Resumed | Cowen | Market Perform |
Oct-14-21 | Initiated | Redburn | Buy |
Jul-14-21 | Downgrade | Kepler | Buy → Hold |
Jun-03-21 | Initiated | Goldman | Neutral |
Oct-06-20 | Resumed | BofA Securities | Buy |
Sep-28-20 | Upgrade | Kepler | Hold → Buy |
Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
Aug-20-20 | Resumed | JP Morgan | Overweight |
Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
Jan-07-20 | Initiated | Citigroup | Neutral |
Dec-26-19 | Resumed | BofA/Merrill | Underperform |
Nov-15-19 | Initiated | Stifel | Hold |
Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership - BioSpace
Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics - MSN
Qiagen and Gencurix partner for oncology tests - MSN
Qiagen’s Voting Rights Notification Highlights BlackRock’s Influence - TipRanks
BlackRock’s Significant Stake in Qiagen Revealed - TipRanks
Qiagen (QGEN) Partners with Gencurix to Enhance Oncology Diagnos - GuruFocus
Qiagen, Gencurix Launch Oncology Testing Development Partnership - MarketScreener
Qiagen and Gencurix partner for oncology tests (QGEN:NYSE) - Seeking Alpha
QIAGEN, GENCURIX announce QIAcuity Digital PCR IVD Assay Development Partnership - marketscreener.com
QGEN Stock Rises in After Market Following Partnership With Incyte - MSN
Qiagen and Incyte announce precision medicine collaboration - BioSpectrum Asia
Should You Add QIAGEN Stock to Your Portfolio for Now? - MSN
Qiagen and Incyte to develop diagnostic panel for myeloproliferative neoplasms - Medical Device Network
QIAGEN, Incyte Partner to Develop NGS-Based Diagnostic Panel for Rare Blood Cancers - MarketScreener
QIAGEN And Incyte Partner To Create New Test For Rare Blood Cancers - Nasdaq
QIAGEN and Incyte Announce Precision Medicine Collaboration to D - GuruFocus
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) | QGEN Stock News - GuruFocus
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) - Yahoo Finance
QIAGEN expands portfolio for MRD testing in oncology with two partnerships - MSN
Qiagen Announces Significant Shareholding Notification - TipRanks
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape - GlobeNewswire Inc.
Qiagen Reports Change in Voting Rights Held by BlackRock - TipRanks
Qiagen Announces Voting Rights Notification by AFM - TipRanks
Here's Why Qiagen (QGEN) is a Strong Momentum Stock - Yahoo Finance
Qiagen (NYSE:QGEN) Receives Average Rating of “Hold” from Brokerages - Defense World
QIAGEN (QGEN) Partners with Tracer Biotechnologies for MRD Assays - GuruFocus
Qiagen (QGEN) Up 8.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
QGEN Partners with Tracer Biotechnologies to Advance Cancer Test - GuruFocus
Qiagen (NYSE:QGEN) Sees Large Increase in Short Interest - Defense World
Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors - marketscreener.com
Qiagen N.V. (QGEN) Expands MRD Testing with Tracer and Foresight Partnerships - MSN
QGEN Partners with Tracer Biotechnologies to Advance Cancer Testing | QGEN Stock News - GuruFocus
Qiagen, Tracer Biotechnologies announce strategic partnership - TipRanks
Transcript : Qiagen N.V. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 09 - MarketScreener
Qiagen N.V. Reports Significant Voting Rights Held by BlackRock - TipRanks
Forensic Genomics Market Research 2025Global Trends, Opportunity, and Forecasts 2020-2030 - GlobeNewswire Inc.
Why Qiagen (QGEN) is a Top Growth Stock for the Long-Term - Yahoo Finance
Here's Why Qiagen (QGEN) is a Strong Value Stock - Yahoo Finance
QGEN Stock to Gain From Expanding Oncology Portfolio via New Alliances - Yahoo Finance
QIAGEN NV : Receives a Buy rating from Deutsche Bank - marketscreener.com
Qiagen expands portfolio for minimal residual disease testing in oncology - BioSpectrum Asia
Foresight Diagnostics and Qiagen Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma - marketscreener.com
Qiagen Enters Partnerships, Expands Portfolio for Minimal Residual Disease Testing in Oncology - marketscreener.com
QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships - Business Wire
Foresight Diagnostics And Qiagen Announce Strategic Partnership To Advance Development Of Companion Diagnostic Kits For Lymphoma - marketscreener.com
Qiagen (QGEN) Forms Strategic Alliance with Foresight Diagnostic - GuruFocus
Qiagen (QGEN) Forms Strategic Alliance with Foresight Diagnostics | QGEN Stock News - GuruFocus
Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma - marketscreener.com
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):